Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03495921
Title Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma (VITA)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Gradalis, Inc.
Age Groups: adult | child | senior
Covered Countries USA

No variant requirements are available.